<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01035801</url>
  </required_header>
  <id_info>
    <org_study_id>IN105-CT1-005-09</org_study_id>
    <nct_id>NCT01035801</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Insulin (IN-105) in Type 1 Diabetes Patients</brief_title>
  <official_title>An OpenLabel, Multicenter, Non-randomized, ActiveControlled, SingleDose Escalation, Study to Evaluate the Pharmacodynamics,Pharmacokinetics,Safety, and Tolerability of IN-105 Under Fed Conditions In Patients With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocon Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocon Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see whether IN-105 (oral insulin) is able to control increase
      in blood glucose after eating a meal. This study will also tell whether single tablet of
      IN-105 is safe for patients with Type 1 diabetes mellitus who are currently taking insulin
      injections.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study was temporarily paused due to an unanticipated bioanalytical issue.
  </why_stopped>
  <start_date type="Actual">August 21, 2010</start_date>
  <completion_date type="Actual">March 12, 2011</completion_date>
  <primary_completion_date type="Actual">March 12, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (Insulin and Blood Glucose)</measure>
    <time_frame>0-130 min</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC (Insulin and Blood Glucose)</measure>
    <time_frame>0-70 min, 0-190 min and 0-250 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>IN105</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prandial Oral Insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Lispro Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IN-105</intervention_name>
    <description>Prandial Oral Insulin</description>
    <arm_group_label>IN105</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro Injection</intervention_name>
    <description>Insulin Lispro Injection</description>
    <arm_group_label>Insulin Lispro Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients between the ages of 18-45 years inclusive

          2. Established diagnosis of T1DM for at least 1-year

          3. Body mass index of 18.5-29.9 kg/m2 inclusive

          4. Stable weight with no more than 5 kg gain or loss within 3 months of screening

          5. HbA1c ≤ 8.0%

          6. On stable insulin or an insulin analogue regimen for at least 3 months

        Exclusion Criteria:

          1. Any hypersensitivity or allergy

          2. Positive urine ketones test at screening visit.

          3. ECG abnormality

          4. total daily insulin &gt;1 IU/kg and/or &gt;0.7 IU/Kg of basal insulin and/or &gt;0.6 IU/Kg of
             prandial insulin.

          5. Patient with a clinically significant abnormality

          6. Evidence of severe secondary complications of diabetes

          7. History of drug or alcohol dependence or abuse

          8. Patients currently on systemic or inhaled glucocorticoids or other drugs, which may
             affect glycemic control.

          9. Patients treated with blood-glucose lowering drugs other than insulin or insulin
             analogues in the last 4 weeks prior to screening or during the study

         10. History of two or more severe episodes of hypoglycemia (defined by ADA criteria)
             within 6 months prior to screening and/or patients with history of low blood glucose
             level episodes suggestive of hypoglycemia unawareness (loss of warning symptoms of
             hypoglycemia). Investigator to assess this criterion based on the subject filled
             questionnaire.

         11. Any hospitalization or emergency room visit due to poor diabetes control within 6
             months prior to screening.

         12. Impaired hepatic function (ALT or AST value greater than 2 X Upper limit of reference
             range and/or serum bilirubin ≥1.5 X Upper limit of reference range at the screening
             visit).

         13. Impaired renal function (serum creatinine ≥1.5 X Upper limit of reference range at
             screening).

         14. Hemoglobinopathies, haemolytic anaemia, anaemia of chronic disease, or any factor
             affecting the measurement of HbA1c.

         15. Any electively planned surgery requiring hospitalization during the study period.

         16. Pregnancy, lactation, or planned pregnancy during the study duration.

         17. The patient has received another investigational drug within 6 weeks prior to
             screening

         18. Mental incapacity, unwillingness or language barriers precluding adequate
             understanding or co-operation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. K.M. Prasanna Kumar, MD, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>CEO and Consultant Endocrinologist, Bangalore Diabetes Hospital, #16/M, Miller tank Bed Area, Thimmaiah Road, Vasanthnagar, Bangalore-560052</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Aravind R Sosale, DNB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, Diacon Hospital,Diabetes Care and Research Centre, 359-360, 19th Main, Ist Block,Rajajinagar,Bangalore-560010.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Sanjay Kalra, MD, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bharti Research Institute of Diabetes &amp; Endocrinology (BRIDE), Bharti Hospital, Wazir Chand Colony, Kunjpura, karnal, Hariyana- 132001</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Bipin Kumar Sethi, MD, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Care Hospital, Road 1, Banjara Hills, Hyderabad - 500034</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Neeta Deshpande, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Belgaum Diabetic Centre, Ground floor,Beside mahila Vastu Bhander, Maruti Gali, Belgaum- 590001</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Care Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bharti Research Institute of Diabetes and Endocrinology</name>
      <address>
        <city>Karnal</city>
        <state>Hariyana</state>
        <zip>132001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diacon Hospital,(Diabetes Care and Research Centre)</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bangalore Diabetes Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560052</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belgaum Diabetic Centre</name>
      <address>
        <city>Belgaum</city>
        <state>Karnataka</state>
        <zip>590001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2009</study_first_submitted>
  <study_first_submitted_qc>December 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2009</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

